Feinstein Institutes discovery may have implications for diabetes management and therapy

July 10, 2019

Theodoros Zanos, PhD, head of the Neural & Data Science Lab & assistant professor at the Institute of Bioelectronic Medicine, The Feinstein Institutes for Medical Research, and his collaborators, discovered how the vagus nerve relays signals from the periphery to the brain to help regulate glucose, potentially uncovering a new way to measure blood glucose levels. This finding progresses research into future bioelectronic medicine treatments and diagnostics for metabolic syndrome and diabetes. The findings were published today in the Springer Nature journal, Bioelectronic Medicine.

In humans, glucose is the primary sugar for high energy demanding cells in brain, muscle and peripheral neurons. Any deviation of normal blood glucose levels for an extended period of time can be dangerous or even fatal, so regulation of blood glucose levels is a biological imperative. Prior research showed that the vagus nerve, which connects to many major organs in the body and communicates changes in the body to the brainstem, plays a role in regulating metabolism. Because the specifics of how this was accomplished were largely unknown, Dr. Zanos and his colleagues' sought to identify the specific signals relayed from the periphery to the brain that responded to changes in glucose levels. By deciphering these signals, they can better understand when and how to stimulate the vagus nerve to regulate metabolism.

"One of our goals is to understand the neural code of the vagus nerve as it related to different conditions, because we believe by listening to and stimulating this nerve, we can open new possibilities to diagnose and treat various diseases," said Dr. Zanos. "The vagus nerve is one of the major information conduits of the body with an average of 100,000 nerve fibers, making this code difficult to pick up and decipher, so we have a lot to learn. We're excited to demonstrate in this most recent study that the vagus nerve of a mouse transports important signals from the periphery to the central nervous system related to glucose homeostasis - this discovery gets us closer to new technologies that will have the potential of helping many patients living with various metabolic diseases."

Dr. Zanos collaborated on this study with Feinstein Institutes researchers Emily Battinelli Masi, PhD, Todd Levy, MS, Tea Tsaava, MD, Chad E. Bouton, MS, and Sangeeta S. Chavan, PhD. Also co-authoring the article, titled "Identification of hypoglycemia-specific neural signals by decoding murine vagus nerve activity," was Feinstein Institutes President and CEO Kevin J. Tracey, MD.

"This discovery by Dr. Zanos and our bioelectronic medicine researchers give us new understanding of the body's neural signaling and offers hope for diabetes management," said Dr. Tracey.

Bioelectronic medicine is a new approach to treating and diagnosing disease and injury that has emerged from the Feinstein Institutes' labs. It represents a convergence of molecular medicine, neuroscience and bioengineering. Bioelectronic medicine uses device technology to read and modulate the electrical activity within the body's nervous system, opening new doors to real-time diagnostics and treatment options for patients.

Last year, Dr. Zanos and his collaborators were the first to decode specific signals the nervous system uses to communicate immune status and inflammation to the brain. Identifying these neural signals and what they're communicating about the body's health was a step forward for bioelectronic medicine as provided insight into diagnostic and therapeutic targets, and device development. Those findings were published in Proceedings of the National Academy of Sciences (PNAS).
-end-


Northwell Health

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.